BeyondSpring files $11.9 million at-the-market offering with Citizens

BeyondSpring Inc. entered into an Open Market Sale Agreement with Citizens JMP Securities, LLC dated September 29, 2026, covering the potential sale of up to 9,200,000 ordinary shares. Under the agreement, BeyondSpring may offer and sell 9,200,000 of its ordinary shares from time to time through Citizens, acting as agent.¹ The shares trade on Nasdaq under the symbol BYSI, and the last reported sale price on September 25, 2026 was $0.7772 per share.¹

Citizens will earn a commission of up to 3.0% of the gross sales price on each share sold, with the exact number of shares to be mutually agreed.¹

Because of SEC rules limiting sales by smaller companies, the company's public float was calculated at approximately $41.8 million, based on 35,750,770 shares held by non-affiliates as of August 3, 2026, at a per-share price of $1.17.¹ In the prior twelve months, BeyondSpring had already sold 800,000 ordinary shares for $2.0 million gross proceeds under a separate securities purchase agreement with Ray Beauty Group Limited dated November 17, 2025.¹ As a result, the company may sell shares under the new agreement up to a total offering price of $11,942,800 through Citizens.¹

Assuming the September 25 price of $0.7772 per share, gross proceeds from the full offering would be approximately $7.15 million.¹ BeyondSpring said it intends to use net proceeds to fund research and development and for general corporate purposes.¹

Separately, on September 28, 2026, BeyondSpring signed a share purchase and collaboration agreement under which it agreed to sell to Biolin Investment Limited the full share capital of BeyondSpring Ltd., its wholly owned British Virgin Islands subsidiary that holds its interest in Dalian Wanchunbulin Pharmaceuticals Ltd.¹ In exchange, the investor will complete the China portion of the DUBLIN-4 global Phase 3 trial of Plinabulin combined with docetaxel in previously treated non-squamous NSCLC patients.¹